Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations

Walid Shalata, Zoe Gabrielle Attal, Adam Solomon, Sondos Shalata, Omar Abu Saleh, Lena Tourkey, Fahed Abu Salamah, Ibrahim Alatawneh, Alexander Yakobson

    Research output: Contribution to journalReview articlepeer-review


    Melanoma, a malignant neoplasm originating from melanocytes, stands as one of the most prevalent cancers globally, ranking fifth in terms of estimated new cases in recent years. Its aggressive nature and propensity for metastasis pose significant challenges in oncology. Recent advancements have led to a notable shift towards targeted therapies, driven by a deeper understanding of cutaneous tumor pathogenesis. Immunotherapy and tyrosine kinase inhibitors have emerged as promising strategies, demonstrating the potential to improve clinical outcomes across all disease stages, including neoadjuvant, adjuvant, and metastatic settings. Notably, there has been a groundbreaking development in the treatment of brain metastasis, historically associated with poor prognosis in oncology but showcasing impressive results in melanoma patients. This review article provides a comprehensive synthesis of the most recent knowledge on staging and prognostic factors while highlighting emerging therapeutic modalities, with a particular focus on neoadjuvant and adjuvant strategies, notably immunotherapy and targeted therapies, including the ongoing trials.

    Original languageEnglish
    Article number5794
    JournalInternational Journal of Molecular Sciences
    Issue number11
    StatePublished - 1 Jun 2024


    • BRAF
    • brain metastasis
    • immunotherapy
    • melanoma
    • metastatic
    • skin cancer
    • tyrosine kinase inhibitors

    ASJC Scopus subject areas

    • Catalysis
    • Molecular Biology
    • Spectroscopy
    • Computer Science Applications
    • Physical and Theoretical Chemistry
    • Organic Chemistry
    • Inorganic Chemistry


    Dive into the research topics of 'Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations'. Together they form a unique fingerprint.

    Cite this